Holen Sie sich die Stockscreener-App
742.91
0.69%
5.08
Handel nachbörslich:
742.46
-0.45
-0.06%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Hims & Hers gains after court rejects Eli Lilly’s case against Willow - Yahoo Finance
BMO Capital Markets Reaffirms ‘Buy Rating’ on Eli Lilly Stock (LLY) - TipRanks
Gastric Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Eli Lilly and Company, BeiGene, Hutchison MediPharma, Astellas Pharma, Henlix - Barchart.com
PRESSR: Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity - TradingView
Is Novo Nordisk Stock a Buy Now? - The Motley Fool
Stomach Cancer Treatment Market Review 2020-2024 and Forecast 2025-2030 - GlobeNewswire Inc.
Fueled by Lilly's Lebanon investment, local builds future in biotech at Ivy Tech - reporter.net
Analyst Forecasts $25 Billion of Annual Sales for Eli Lilly’s (LLY) New Weight-Loss Pill - TipRanks
Eli Lilly's once-daily obesity pill passes phase 3 trials - 조선일보
BMO Capital Affirms Eli Lilly (LLY)’s ‘Outperform’ Rating on Weight Loss Drug Prospects - Yahoo Finance
Eli Lilly's New Drugs Beyond Mounjaro And Zepbound Boost Sales - Barchart.com
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales - Nasdaq
What's Going On With Novo Nordisk Stock Tuesday?Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY) - Benzinga
Eyes on Asia: Lilly, Fosun, RemeGene - BioXconomy
Lilly Ends Two Mid-Stage Trials for Second Obesity Asset - BioSpace
Is Eli Lilly and Company’s growth already priced inJuly 2025 Decliners & Fast Moving Stock Watchlists - خودرو بانک
Eli Lilly & Co: Strong Buy Rating Driven by Promising Weight Loss Drug and Innovative Subscription Model - TipRanks
Recently, Eli Lilly's obesity treatment "Munzaro" has been released in Korea and interest in obesity.. - 매일경제
Recently, Eli Lilly's obesity treatment Maunzaro was released in Korea, and as interest in obesity t.. - 매일경제
Eli Lilly and Company (LLY) Halts UK Mounjaro Shipments Ahead of Planned Price Increase - uk.finance.yahoo.com
Can trapped investors hope for a rebound in Eli Lilly and CompanyTrade Performance Summary & Detailed Earnings Play Alerts - Newser
Eli Lilly’s SWOT analysis: stock’s growth potential in obesity market faces challenges - Investing.com
Eli Lilly (LLY) Partners with JD.com to Sell Weight-Loss Drugs in China - TipRanks
ESC25: Novo's Wegovy slashes CV risk by 57% over Lilly's Zepbound in real-world study - FirstWord Pharma
Novo Nordisk Says Wegovy Cuts Heart Risk by 57% Compared With Eli Lilly’s Obesity Drug - The Wall Street Journal
Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data | LLY Stock News - Quiver Quantitative
Can you recover from losses in Eli Lilly and CompanyJuly 2025 Levels & Verified Chart Pattern Trade Signals - Newser
HSBC Upgrades Eli Lilly (LLY) to Hold, Lifts Price Target to $700 - Yahoo Finance
Intraday pattern recognizer results for Eli Lilly and CompanyPortfolio Risk Report & Fast Exit Strategy with Risk Control - Newser
Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell — And Trump Investment Hints Boost Defense Stocks - inkl
Eli Lilly is close to launching the strongest weight-loss drug ever. Somehow, gym bros are already taking it to shred fat. - Business Insider
Eli Lilly and Company (LLY): A Bull Case Theory - MSN
Sector ETF performance correlation with Eli Lilly and Company2025 Geopolitical Influence & Consistent Profit Trading Strategies - Newser
Eli Lilly and Company (LLY) Needs To Get A Weight Loss Pill Out, Says Jim Cramer - Yahoo Finance
Pharmaceutical Cos. Back Lilly In Mich. Insulin Pricing Probe - Law360
Jim Cramer Sees Big Potential in Eli Lilly’s Weight-Loss and Diabetes Pill - Yahoo Finance
The Zacks Analyst Blog Highlights Lilly, Oracle, Procter & Gamble and Comstock Holding Companies - ca.finance.yahoo.com
Eli Lilly (NYSE:LLY) vs Novo Nordisk (NYSE:NVO): Growth Premium vs Value Upside - tradingnews.com
Eli Lilly (NYSE:LLY) Stock Price Trading at $732 as GLP-1 Sales Surge and Drug Pricing Risks Rise - tradingnews.com
Is Eli Lilly Stock A Buy As The Company Aims For Weight-Loss Pill Approval? - Investor's Business Daily
Eli Lilly Stock: Is LLY Underperforming the Healthcare Sector? - Yahoo Finance
Eli Lilly Temporarily Stops U.K. Shipments of Its Weight-Loss Drug - TipRanks
Eli Lilly Partners with JD Health for Direct-to-Consumer Obesity and Diabetes Drug Sales - AInvest
JD Health (06618.HK) has reached a strategic cooperation agreement with Eli Lilly and Co in China. - 富途牛牛
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Partners With China Tech Giant for Obesity Drug Sales - Bloomberg
Eli Lilly to offer UK discount on Mounjaro weight-loss jabs - The Independent
Decoding Insider Activity at Eli Lilly: A Closer Look at Recent Share Sales and Buying Conviction - AInvest
Top Stock Reports for Eli Lilly, Oracle & Procter & Gamble - Nasdaq
Eli Lilly CIO Susan Ridlen retiring - Pensions & Investments
Eli Lilly (LLY) technical analysisEli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (LLY) Reports Positive Outcomes for Verzenio in Breast Cancer Trial - uk.finance.yahoo.com
Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals - insights.citeline.com
Stockpiling frenzy prompts Lilly to suspend UK Mounjaro supply - FirstWord Pharma
U-turn on Mounjaro price hike: drug giant scales back planned rise after backlashnew costs revealed in full - Daily Mail
Eshelman Ventures, Eli Lilly back $11M round for RTP firm - The Business Journals
Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
UK Patients Scramble For Mounjaro As Eli Lilly's 170% Price Hike Plan Sparks Shortages, Health Fears - Benzinga
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro By Reuters - Investing.com
HSBC Upgrades Eli Lilly Amid 'More Sensible' Market Expectations for Weight Loss Pill - MarketScreener
Eli Lilly could bring first widely available GLP‑1 pill for obesity, diabetes to market this year - AOL.com
Stevens Capital Closes Out Position in Eli Lilly - The Motley Fool
0.43%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):